Study to Assess Bioavailability of GLPG1690 Given as Oral Capsule or Tablet

Inclusion criteria

• Male between 18-50 years of age, inclusive
• Body mass index (BMI) between 18-30 kg/m2, inclusive, with a weight of at least 50 kg.
• Judged by the investigator to be in good health based upon the results of a medical history, physical examination, vital signs, 12-lead ECG, and laboratory findings.
• Discontinuation of all medications except occasional paracetamol at least 2 weeks or 5 half-lives prior to the first study drug administration
• Non-smokers and not using any nicotine-containing products.
• Negative urine drug screen and alcohol breath test.
• Current sexually active male agrees to use adequate contraception/preventive exposure measures from the time of first dose of study drug, during the study and until 12 weeks after the last study drug dose.
• Subjects should be willing to consume the non-vegetarian high-fat and high-calorie breakfast.
• Able and willing to sign the ICF

Exclusion criteria

• Known hypersensitivity to study drug ingredients or a significant allergic reaction to any drug
• Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or any history of hepatitis from any cause with the exception of hepatitis A.
• History of or a current immunosuppressive condition.
• Presence of abnormal liver function. Diagnosis of disease of Gilbert is accepted. Retesting is allowed.
• Renal function with an estimated creatinine clearance <80 ml/min based on the Cockcroft-Gault formula. Retesting is allowed.
• Presence of any condition known to interfere with absorption, distribution, metabolism or excretion of drugs.
• History of malignancy within the past 5 years
• Clinically relevant abnormalities detected on ECG regarding either rhythm or conduction (e.g., QTcF >450 ms, or a known long QT syndrome).
• Clinically relevant abnormalities detected on vital signs.
• Dietary requirements precluding participation in the study
• Significant blood loss (including blood donation [≥450 mL]), or transfusion of any blood product within 8 weeks prior to the signing of ICF.
• Active drug or alcohol abuse within 2 years prior to the initial study drug administration.
• Consumption of large quantities of caffeinated coffee or tea (>6 cups/day), or equivalent.
• Concurrent participation or participation in a drug or drug/device investigational research study.
• Subjects who participated in a previous study with the same compound (GLPG1690).
• Investigator or any sub-investigator, or other staff or relative.
• Any condition or circumstances that in the opinion of the investigator may make a subject unlikely or unable to complete the study or comply with study procedures and requirements.